FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention relates to a pharmaceutical composition. Disclosed is a pharmaceutical composition for treating non-alcoholic fatty liver dystrophy derived from the following medicinal raw materials: 26.25 g to 180 g of silybin, 45 g to 195 g of phospholipid, 75 g to 600 g of Puer tea extract; from 9.375 g to 120 g of vitamin E.
EFFECT: technical result is effective treatment of non-alcoholic fatty liver dystrophy.
12 cl, 6 tbl, 1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN AND RADIX PUERARIAE EXTRACT | 2016 |
|
RU2697670C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN | 2016 |
|
RU2697523C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN, VITAMIN E AND L-CARNITINE | 2016 |
|
RU2700793C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN AND L-CARNITINE | 2016 |
|
RU2699011C2 |
| PHARMACEUTICAL COMBINATION CONTAINING SILYBIN | 2016 |
|
RU2695224C2 |
| USE OF PEGYLATED RECOMBINANT CHIMERIC MOUSE FIBROBLAST-21 GROWTH FACTOR OR ITS PHARMACEUTICALLY ACCEPTABLE SALT IN COMPOSITION OF DRUGS FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | 2018 |
|
RU2785582C2 |
| COMPOSITION FOR TREATING METABOLIC OXIDATIVE CHANGES IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) | 2014 |
|
RU2694896C2 |
| COMPOSITION FOR PREVENTING OR TREATING FATTY LIVER DISEASES | 2015 |
|
RU2664696C2 |
| COMPOSITION AND METHOD OF PREVENTION, REMOVAL OF SYMPTOMS OR THERAPEUTIC EFFECT ON LIVER DAMAGE | 2020 |
|
RU2810601C2 |
| PHARMACEUTICAL COMBINATION, COMPOSITION, AND COMBINED COMPOSITION, CONTAINING GLUCOKINASE ACTIVATOR AND PPAR RECEPTOR ACTIVATOR, AND THEIR PREPARATION METHOD, AND THEIR USE | 2019 |
|
RU2781638C2 |
